These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 20038315)
1. [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib]. Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315 [TBL] [Abstract][Full Text] [Related]
2. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901 [TBL] [Abstract][Full Text] [Related]
3. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Han SW; Kim TY; Lee KH; Hwang PG; Jeon YK; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ Lung Cancer; 2006 Nov; 54(2):201-7. PubMed ID: 16956694 [TBL] [Abstract][Full Text] [Related]
4. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Zhang XT; Li LY; Mu XL; Cui QC; Chang XY; Song W; Wang SL; Wang MZ; Zhong W; Zhang L Ann Oncol; 2005 Aug; 16(8):1334-42. PubMed ID: 15956035 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Shukuya T; Takahashi T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Takahashi K; Yamamoto N Cancer Sci; 2011 May; 102(5):1032-7. PubMed ID: 21272159 [TBL] [Abstract][Full Text] [Related]
6. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993 [TBL] [Abstract][Full Text] [Related]
7. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. Kimura H; Kasahara K; Shibata K; Sone T; Yoshimoto A; Kita T; Ichikawa Y; Waseda Y; Watanabe K; Shiarasaki H; Ishiura Y; Mizuguchi M; Nakatsumi Y; Kashii T; Kobayashi M; Kunitoh H; Tamura T; Nishio K; Fujimura M; Nakao S J Thorac Oncol; 2006 Mar; 1(3):260-7. PubMed ID: 17409866 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683 [TBL] [Abstract][Full Text] [Related]
9. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib. Takeda M; Okamoto I; Nakagawa K J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417 [TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Sone T; Kasahara K; Kimura H; Nishio K; Mizuguchi M; Nakatsumi Y; Shibata K; Waseda Y; Fujimura M; Nakao S Cancer; 2007 May; 109(9):1836-44. PubMed ID: 17387741 [TBL] [Abstract][Full Text] [Related]
11. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455 [TBL] [Abstract][Full Text] [Related]
18. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Taniguchi K; Okami J; Kodama K; Higashiyama M; Kato K Cancer Sci; 2008 May; 99(5):929-35. PubMed ID: 18325048 [TBL] [Abstract][Full Text] [Related]
19. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Cappuzzo F; Toschi L; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Cancellieri A; Magrini E; Bemis L; Franklin WA; Crino L; Bunn PA; Hirsch FR; Varella-Garcia M Br J Cancer; 2005 Dec; 93(12):1334-40. PubMed ID: 16288303 [TBL] [Abstract][Full Text] [Related]
20. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. Sutiman N; Tan SW; Tan EH; Lim WT; Kanesvaran R; Ng QS; Jain A; Ang MK; Tan WL; Toh CK; Chowbay B J Thorac Oncol; 2017 Mar; 12(3):529-538. PubMed ID: 27908825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]